Orphan Drug Monopoly Extension is federal incentives meant for neglected diseases get used to privatize widely available medicines. It sits in the Incentives dimension (INC) of the Human Behavior Taxonomy™ as element HBT-INC-0197, within the Healthcare Perverse Pattern family. The core principle: federal incentives meant for neglected diseases get used to privatize widely available medicines. In incentive terms, it matters because it changes the payoff people perceive before they choose — which means it can be designed for, or exploited.
Scientific Definition
Federal incentives meant for neglected diseases get used to privatize widely available medicines.
Plain-English Definition
Federal incentives meant for neglected diseases get used to privatize widely available medicines.
Feynman Explanation
Take a free compound, rename it, and re-rent it.
Core Principle
Federal incentives meant for neglected diseases get used to privatize widely available medicines.
Mechanisms
Pending editorial review.
Federal incentives meant for neglected diseases get used to privatize widely available medicines.
Pending editorial review.
Pending editorial review.
Regulatory loopholes are revenue if you read them creatively.
Pending editorial review.
Pending editorial review.
Inputs (Triggers)
Pending editorial review.
Outputs (Behaviors)
Pending editorial review.
Behavioral Signature
Take a free compound, rename it, and re-rent it.
Examples
- Repackaged decades-old drugs granted orphan exclusivity at 50–100x prices.
- Regulatory loopholes are revenue if you read them creatively.
Pending editorial review.
Original analysis from The Incentives Lab — how this element behaves inside real payoff structures.
Why this element matters to incentive design
This element is common enough to feel like human nature and specific enough to be engineered around. The mechanism underneath it is straightforward: federal incentives meant for neglected diseases get used to privatize widely available medicines. You can recognize it in the field by its signature: take a free compound, rename it, and re-rent it. Every element in the Incentives dimension changes the perceived payoff of an action before the action happens, which is exactly where incentive design has leverage.
How it gets exploited
Left undesigned, regulatory loopholes are revenue if you read them creatively. It is amplified whenever regulatory loopholes are revenue if you read them creatively. Inside organizations that shows up as regulatory loopholes are revenue if you read them creatively. The pattern is the same one Goodhart's Law describes: the measurable proxy attracts the effort, and the purpose behind it quietly loses funding.
How the Lab designs around it
The redesign move is to tighten orphan eligibility. Outcome-tied price caps. The leverage is not in explaining the behavior to people. It is in changing what the behavior earns.
Famous Experiments
Pending editorial review.
Design Principles
- Tighten orphan eligibility. Outcome-tied price caps.
Measurement Approaches
Pending editorial review.
Evidence
Pending editorial review.
Pending editorial review.
The Perverse Incentive Lens™
How this behavior is exploited — and how to redesign around it.
- Tighten orphan eligibility. Outcome-tied price caps.
Pending editorial review.
Pending editorial review.
Interactive Mini Network
Click any neighbor to re-center the graph and follow the threads of connection.
Knowledge Graph Neighbors
Auto-linked to the rest of the Human Behavior Taxonomy by family, domain, dimension, and shared keywords.
Productivity targets compress visits, raising misdiagnosis and burnout.
A federal mandate intended to lower drug costs for the poor became a profit engine for hospitals and contract pharmacies.
Liability exposure pushes clinicians to order tests for legal protection rather than clinical need.
Federal reimbursement rules incentivize cycling seniors through hospitalizations to upgrade billing categories.
Paying providers per procedure rewards more procedures, not better outcomes.
Systems paid per filled bed have weak incentives to invest in prevention or community health.
Opaque billing rules create lucrative work for administrators and revenue-cycle firms instead of care.
Insurers profit when claims are denied, delayed, or abandoned.
Hospital group-purchasing and opaque contracting inflate device costs far above marginal cost.
Sales bonuses and prescriber relationships fueled mass over-prescription and an addiction crisis.
Drug companies optimize for high-margin chronic conditions, not cures.
Specialists earn more for procedures than primary care for prevention.
Where Orphan Drug Monopoly Extension is cited in the corpus
Essays, field guides, and diagnostics from The Incentives Lab that apply this element.
- Field guideIncentives: definition, types, examples
The parent field guide for this element.
- ReferenceThe laws of incentives
Goodhart, Campbell, and the Cobra Effect.
- CourseIncentives 101
The free ten-part primer on reading a payoff structure.
- ReferenceThe incentive glossary
Definitions for every mental model, bias, and fallacy in the corpus.
- ReferenceThe Periodic Table of Human Behavior
The full 1,267-element map this page belongs to.
Questions about Orphan Drug Monopoly Extension
- What is Orphan Drug Monopoly Extension?
- Orphan Drug Monopoly Extension is federal incentives meant for neglected diseases get used to privatize widely available medicines. It sits in the Incentives dimension (INC) of the Human Behavior Taxonomy™ as element HBT-INC-0197, within the Healthcare Perverse Pattern family. The core principle: federal incentives meant for neglected diseases get used to privatize widely available medicines. In incentive terms, it matters because it changes the payoff people perceive before they choose — which means it can be designed for, or exploited.
- What is an example of Orphan Drug Monopoly Extension?
- Regulatory loopholes are revenue if you read them creatively. The Incentives Lab catalogs everyday, organizational, and historical instances of this element on its Human Behavior Taxonomy™ page (HBT-INC-0197).
- How is Orphan Drug Monopoly Extension exploited?
- Regulatory loopholes are revenue if you read them creatively.
- How do you design around Orphan Drug Monopoly Extension?
- Tighten orphan eligibility. Outcome-tied price caps.
- Which behavioral dimension does Orphan Drug Monopoly Extension belong to?
- Orphan Drug Monopoly Extension is classified in the Incentives dimension (INC) of the Human Behavior Taxonomy™, family "Healthcare Perverse Pattern", class "Perverse Incentive". Its permanent identifier is HBT-INC-0197 and its evidence grade is C.